Research progress on the effects of different dosing regimens of anti-vascular endothelial growth factor drugs on diabetic retinopathy
10.3760/cma.j.cn511434-20240708-00255
- VernacularTitle:抗血管内皮生长因子药物不同给药方案对糖尿病视网膜病变治疗影响的研究进展
- Author:
Julaiti YISIHARE
1
;
Yanming TIAN
Author Information
1. 新疆医科大学研究生学院, 乌鲁木齐 830011
- Publication Type:Journal Article
- Keywords:
Diabetic retinopathy;
Anti-vascular endothelial growth factor drug;
Dosage regimen;
Pars plana vitrectomy;
Review
- From:
Chinese Journal of Ocular Fundus Diseases
2025;41(1):63-68
- CountryChina
- Language:Chinese
-
Abstract:
Diabetic retinopathy (DR) has become an important cause of irreversible vision loss worldwide. Intravitreal injection of anti-vascular endothelial growth factor (VEGF) drugs is an important method to the treatment of DR. However, the current anti-VEGF treatment regimen is not uniform. Anti-VEGF injection was preferred and then delayed combined with laser had better prognostic effect. The best time for operation was 5-7 days after injection of anti-VEGF drugs. Pars plana vitrectomy, intraoperative and postoperative on-demand anti-VEGF drugs injection can significantly improve patient prognosis and reduce complications, but further research is needed to strike a balance between the economic burden and the number of injections. Various anti-VEGF drugs have their own advantages for different diseases and should be selected according to the characteristics of the diseases and drugs. Anti-VEGF drugs combined with antioxidants may further improve DR outcomes. Future studies should pay more attention to the optimization and personalization of anti-VEGF drugs application programs to meet the therapeutic needs of different patients.
